FDA Pushes Review Time For GSK's Blood Cancer Therapy Added Via Sierra Oncology Acquisition
Portfolio Pulse from Vandana Singh
The FDA has extended the review period for GSK's new drug application for momelotinib, a blood cancer therapy, by three months to September 16, 2023. GSK acquired the therapy through its $1.9 billion acquisition of Sierra Oncology.
June 16, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GSK's momelotinib review period extended by FDA; acquired through $1.9 billion Sierra Oncology acquisition.
The FDA's extension of the review period for GSK's momelotinib is a neutral event for the company's stock price in the short term. While the extension may cause some uncertainty, GSK remains confident in the NDA and the therapy's potential. The acquisition of Sierra Oncology and the development of momelotinib are important for GSK's growth in the blood cancer therapy market, but the short-term impact of this news is neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100